| 二肽基肽酶4及其抑制剂在新型冠状病毒肺炎防治中的研究进展 |
| |
| 引用本文： | 陈志会,杨艳,凃玲,徐西振. 二肽基肽酶4及其抑制剂在新型冠状病毒肺炎防治中的研究进展[J]. 医药导报, 2021, 0(1): 90-93 |
| |
| 作者姓名： | 陈志会 杨艳 凃玲 徐西振 |
| |
| 作者单位： | 华中科技大学同济医学院附属同济医院综合医疗科;华中科技大学同济医学院附属同济医院心血管内科;华中科技大学同济医学院附属同济医院内分泌科 |
| |
| 基金项目： | 国家自然科学基金资助项目(81873512)。 |
| |
| 摘 要： | 新型冠状病毒肺炎(COVID-19)全球大流行给世界健康造成巨大威胁,然而到目前为止尚没有临床证实有效的治疗方法。最近研究显示二肽基肽酶4(DPP4)可能是新型冠状病毒的功能受体,然而DPP4是否直接参与新型冠状病毒与靶细胞的黏附与感染,抑制或者调节DPP4的表达与活性能否阻止COVID-19的发生发展尚需要进一步研究。以往研究显示DPP4抑制剂具有抗炎和抗纤维化作用,因此推测DPP4抑制剂可能具有抑制COVID-19患者高炎症反应状态、改善患者肺纤维化的作用,尚需临床试验加以证实。
|
| 关 键 词： | 二肽基肽酶4抑制剂 新型冠状病毒 新型冠状病毒肺炎 |
Research Progress of Dipeptidyl Peptidase 4 and Its Inhibitors in the Prevention and Treatment of Coronavirus Disease 2019 |
| |
| CHEN Zhihui,YANG Yan,TU Ling,XU Xizhen. Research Progress of Dipeptidyl Peptidase 4 and Its Inhibitors in the Prevention and Treatment of Coronavirus Disease 2019[J]. Herald of Medicine, 2021, 0(1): 90-93 |
| |
| Authors: | CHEN Zhihui YANG Yan TU Ling XU Xizhen |
| |
| Affiliation: | (Department of Geriatric Medicine,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan,430030,China;Division of Cardiology and Department of Internal Medicine,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan,430030,China;Division of Endocrinology and Department of Internal Medicine,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan,430030,China) |
| |
| Abstract: | The pandemic of coronavirus disease 2019(COVID-19)poses a huge threat to the world health,however,no clinical proven effective methods of treatment of COVID-19 were currently available.Recent study indicated that dipeptidyl peptidase 4(DPP4)may be a potential receptor for the SARS-CoV-2,however,whether DPP4 directly participated in the adhesion or infection of SARS-CoV-2 to the target cells,and whether inhibition or modulation of DPP4 activity or expression could prevent the progression of COVID-19 still remain unclear.Previous studies revealed the anti-inflammatory and anti-fibrotic effects of DPP4 inhibitors.Thus,it is speculated that DPP4 inhibitors may play a protective role in inhibiting inflammatory response and pulmonary fibrosis in patients with COVID-19,but it still needs to be further confirmed. |
| |
| Keywords: | Dipeptidyl peptidase 4 inhibitors Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) Coronavirus disease 2019 |
| 本文献已被 维普 等数据库收录！ |
|
